12,372 trials
Atrial Fibrillation
Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016
Systemic Lupus Erythematosus
Primary: Median Time to First SLE Flare Index (SFI) — 183.0; NA; NA; NA Days
Gingivitis
Primary: Evaluation and Comparison of Gingival Health Measured by Bleeding Index (BI) at 24 Weeks — 0.11; 0.19 Score on scale — p=<0.0001
Post Ocular Surgical Inflammation and Pain
Primary: Absence of Cells in Anterior Chamber of the Study Eye — 54; 12 Participants
Refractory Bone or Joint Infections
Primary: Clinical Success at 6 Months — 18; 9; 3 Participants
Multiple Sclerosis · Optic Neuritis
Primary: Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores — -0.04; -0.06; -0.08; -0.06 LogMAR…
Lymphoma, Follicular
Primary: Area Under the Serum Concentration-time Curve at Steady State (AUCtau) — 41002.43; 40099.08 h*ug/mL
Optic, Atrophy, Hereditary, Leber
Primary: Change From Baseline in ETDRS Visual Acuity (Quantitative Score) at Week 48 — 0.380; 0.392 LogMAR — p=0.8890
Acute Respiratory Distress Syndrome · Vitamin D Deficiency · Critical Illness
Primary: All-cause, All-location Mortality to Day 90 — 125; 109 Participants — p=0.26
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — 0.4; 10.4 percentage points — p=<0.0001
Plaque Psoriasis
Primary: Percentage of Participants Who Experienced Grade 3 Local Skin Reactions — 22.2; 6.9; 9.8 percentage of participants
Erythrocyte Transfusion · Beta-Thalassemia
Primary: Percentage of Participants Who Achieved Erythroid Response - Week 13 to Week 24 — 21.0; 4.5 Percentage of participants — p=<0.0001
Plaque Psoriasis
Primary: Percentage of Participants With Treatment Success at Week 8 — 36.5; 8.13 percentage of participants
AML
Primary: Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy — 27.0; 20.4 weeks — p=0.0185
Plaque Psoriasis
Primary: Percentage of Participants With Treatment Success at Week 8 — 38.41; 11.99 percentage of participants